“…12 We worked to understand and adapt to increased levels of coagulation testing as COVID-19 patients developed coagulopathy. 13 We set up new services for the collection of convalescent plasma to lessen the impact and mortality for some patients 14 and supported our institutions' participation in the requisite clinical trials to find new therapies for COVID-19. 15 We responded to shifting needs in our clinical labs by increasing our services where needed to support the clinical care of hospitalized COVID-10 patients, implementing serology for the virus, 16 and shifting our workforce to support the heavy demands of accessioning specimens for the increased testing workload.…”